节拍化疗在乳腺癌中的应用及研究进展
Application and Research Progress of Metronomic Chemotherapy in Breast Cancer
DOI: 10.12677/ACM.2021.1112866, PDF,   
作者: 张 静*：内蒙古民族大学第二临床学院，内蒙古 牙克石；曲洪澜#：内蒙古林业总医院，内蒙古 牙克石
关键词: 节拍化疗；乳腺癌；长春瑞滨；卡培他滨；环磷酰胺；Metronomic Chemotherapy； Breast Cancer； Vinorelbine； Capecitabine； Cyclophosphamide
摘要: 乳腺癌现已跃居全球恶性肿瘤榜首。在乳腺癌的治疗中，虽然现在已经有靶向治疗、内分泌治疗、免疫治疗等多种治疗方式，但化疗作为最经典的治疗方式仍发挥不可或缺的作用。然而其不良反应大、作用不持久、肿瘤间歇期重修复和易耐药等缺点，限制了其临床应用。节拍化疗是随之衍生而来的一种新的治疗方式，采用低量、高频、持续给药方式，通过直接杀死癌细胞、抗肿瘤血管生成、抗癌免疫应答的激活等机制发挥抗肿瘤的作用，进而延缓肿瘤的进展及转移。现对节拍化疗在乳腺癌中应用及研究进展综述如下。
Abstract: Breast cancer has ranked the top of the global malignant tumors. In the treatment of breast cancer, although targeted therapy, endocrine therapy, immunotherapy and other treatments are available, chemotherapy as the most classical treatment still plays an indispensable role. However, its clinical application is limited due to serious adverse reactions, unsustainable effect, intermittent repair and easy drug resistance. Metronomic chemotherapy is a new therapeutic method derived from it, which adopts low-dose, high frequency continuous administration to play an anti-tumor role by direct tumor cell death, antiangiogenic and activation of the anticancer immune response, so as to delay tumor progression and metastasis. The application and research progress of metronomic chemotherapy in breast cancer are reviewed as follows.
文章引用：张静, 曲洪澜. 节拍化疗在乳腺癌中的应用及研究进展[J]. 临床医学进展, 2021, 11(12): 5855-5859. https://doi.org/10.12677/ACM.2021.1112866

参考文献

[1] Browder, T., Butterfield, C.E., Kräling, B.M., Shi, B., Marshall, B., O’Reilly, M.S. and Folkman, J. (2000) Antiangiogenic Scheduling of Chemotherapy Improves Efficacy against Experimental Drug-Resistant Cancer. Cancer Research, 60, 1878-1886.
[2] Klement, G., Baruchel, S., Rak, J., Man, S., Clark, K., Hicklin, D.J., Bohlen, P. and Kerbel, R.S. (2006) Continuous Low-Dose Therapy with Vinblastine and VEGF Receptor-2 Antibody Induces Sustained Tumor Regression without Overt Toxicity. Journal of Clinical Investigation, 105, R15-R24. [Google Scholar] [CrossRef] 
[3] Hanahan, D., Bergers, G. and Bergsland, E. (2000) Less Is More, Regularly: Metronomic Dosing of Cytotoxic Drugs Can Target Tumor Angiogenesis in Mice. Journal of Clinical Investigation, 105, 1045-1047. [Google Scholar] [CrossRef] 
[4] Kerbel, R.S. (2015) A Decade of Experience in Developing Preclinical Models of Advanced or Early-Stage Spontaneous Metastasis to Study Antiangiogenic Drugs, Metronomic Chemo-Therapy, and the Tumor Microenvironment. The Cancer Journal, 21, 274-283. [Google Scholar] [CrossRef] 
[5] Cazzaniga, M.E., Cordani, N., Capici, S., Cogliati, V., Riva, F. and Cerrito, M.G. (2021) Metronomic Chemotherapy. Cancers (Basel), 13, 2236. [Google Scholar] [CrossRef] [PubMed]
[6] Nasr, K.E., Osman, M.A., Elkady, M.S. and Ellithy, M.A. (2015) Metronomic Methotrexate and Cyclophosphamide after Carboplatin Included Adjuvant Chemotherapy in Triple Negative Breast Cancer: A Phase III Study. Annals of Translational Medicine, 3, 284.
[7] Montagna, E., Bagnardi, V., Cancello, G., et al. (2018) Metronomic Chemotherapy for First-Line Treatment of Metastatic Triple-Negative Breast Cancer: A Phase II Trial. Breast Care (Basel), 13, 177-181. [Google Scholar] [CrossRef] [PubMed]
[8] Wang, X., Wang, S., Huang, H., et al. (2021) Effect of Capecitabine Maintenance Therapy Using Lower Dosage and Higher Frequency vs Observation on Disease-Free Survival Among Patients with Early-Stage Triple-Negative Breast Cancer Who Had Received Standard Treatment: The SYSUCC-001 Randomized Clinical Trial. JAMA, 325, 50-58. [Google Scholar] [CrossRef] [PubMed]
[9] Johnston, S.R. (2010) New Strategies in Estrogen Receptor-Positive Breast Cancer. Clinical Cancer Research, 16, 1979-1987. [Google Scholar] [CrossRef] 
[10] Schwartzberg, L.S., Wang, G., Somer, B.G., Blakely, L.J., Wheeler, B.M., Walker, M.S., Stepanski, E.J. and Houts, A.C. (2014) Phase II Trial of Fulvestrant with Metronomic Capecitabine for Postmenopausal Women with Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer. Clinical Breast Cancer, 14, 13-19. [Google Scholar] [CrossRef] [PubMed]
[11] Li, J.W., Zuo, W.J., Ivanova, D., Jia, X.Q., Lei, L. and Liu, G.Y. (2019) Metronomic Capecitabine Combined with Aromatase Inhibitors for New Chemoendocrine Treatment of Advanced Breast Cancer: A Phase II Clinical Trial. Breast Cancer Research and Treatment, 173, 407-415. [Google Scholar] [CrossRef] [PubMed]
[12] Wildiers, H., Tryfonidis, K., Dal Lago, L., Vuylsteke, P., Curigliano, G., Waters, S., Brouwers, B., Altintas, S., Touati, N., Cardoso, F. and Brain, E. (2018) Pertuzumab and Trastuzumab with or without Metronomic Chemotherapy for Older Patients with HER2-Positive Metastatic Breast Cancer (EORTC 75111-10114): An Open-Label, Randomised, Phase 2 Trial from the Elderly Task Force/Breast Cancer Group. The Lancet Oncology, 19, 323-336. [Google Scholar] [CrossRef] 
[13] Wang, Z., Liu, J., Ma, F., et al. (2021) Safety and Efficacy Study of Oral Metronomic Vinorelbine Combined with Trastuzumab (mNH) in HER2-Positive Metastatic Breast Cancer: A Phase II Trial. Breast Cancer Research and Treatment, 188, 441-447. [Google Scholar] [CrossRef] [PubMed]
[14] Fedele, P., Marino, A., Orlando, L., et al. (2012) Efficacy and Safety of Low-Dose Metronomic Chemotherapy with Capecitabine in Heavily Pretreated Patients with Metastatic Breast Cancer. European Journal of Cancer, 48, 24-29. [Google Scholar] [CrossRef] [PubMed]
[15] Palazzo, A., Dellapasqua, S., Munzone, E., et al. (2018) Phase II Trial of Bevacizumabplus Weekly Paclitaxel, Carboplatin, and Metronomic Cyclophosphamide with or without Trastuzumab and Endocrine Therapy as Preoperative Treatment of Inflammatory Breast Cancer. Clinical Breast Cancer, 18, 328-335. [Google Scholar] [CrossRef] [PubMed]

为你推荐